Evox Therapeutics

Evox Therapeutics is a privately held biotechnology company incorporated in 2016 and headquartered at the Medawar Centre, Oxford Science Park, Oxford, UK. It was founded by Professor Matthew Wood (Oxford University) and Assistant Professor Samir El Andaloussi and Dr Per Lundin (Karolinska Institutet), building on foundational exosome research from those two institutions. Dr Per Lundin currently serves as CEO, and the company employs approximately 58 people as of end-2024.

The company's core platform, ExoEdit™, uses molecular engineering, drug loading, and targeting strategies to modify extracellular vesicles (exosomes) for therapeutic delivery. Engineered exosomes cross natural barriers such as the blood-brain barrier, exhibit broad cellular tropism and superior bioavailability, and offer safety advantages over viral delivery systems.

Evox's pipeline targets rare, genetically driven neurodegenerative diseases including Spinocerebellar Ataxia type 2 (SCA2), ALS, Huntington's disease, and most recently Rett syndrome, the last through a collaboration with the Rett Syndrome Research Trust. The company has raised a total of $156 million across six funding rounds—the latest a Series C in February 2021—backed by investors including the Redmile Group, the Gates Foundation, and Oxford Science Enterprises.

As a pioneer in exosome-based gene editing delivery, Evox is directly relevant to innovations in non-viral delivery systems for genetic medicines, particularly those targeting the central nervous system where conventional approaches face significant barriers.